Cresco Labs Inc. (CRLBF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cresco Labs Inc. (CRLBF) Healthcare & Pipeline Overview

Cresco Labs Inc. stands out in the cannabis sector with a robust portfolio of brands and a multi-state retail presence, catering to both medical and recreational markets while navigating the complexities of regulatory landscapes.

What Is the Investment Thesis for CRLBF?

The company's diverse brand portfolio, including Cresco, High Supply, and Mindy's Edibles, allows it to cater to a wide range of consumer preferences. With a gross margin of 48.6%, Cresco Labs demonstrates strong operational efficiency compared to industry peers. However, the company faces risks associated with its OTC trading status, which may limit liquidity and transparency. Regulatory changes in the cannabis industry could impact market dynamics, making it crucial for Cresco Labs to adapt quickly to maintain its competitive edge. The company's ability to expand its retail footprint and enhance brand recognition will be key drivers of future revenue growth.

Based on FMP financials and quantitative analysis

CRLBF Key Highlights

Market Cap of $258M reflects the company's current valuation in the cannabis sector.

• Gross Margin of 48.6% indicates strong operational efficiency compared to industry standards.
• Profit Margin of -21.3% highlights challenges in achieving profitability amid competitive pressures.
• Beta of 1.71 suggests higher volatility compared to the overall market, indicating potential risk.
• No dividend yield as the company reinvests earnings to support growth initiatives.

Who Are CRLBF's Competitors?

CRLBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CRLBF's Key Strengths?

Diverse brand portfolio catering to various consumer segments.

• Strong operational capabilities with significant cultivation and production capacity.
• Established retail network enhances market presence and consumer access.

What Are CRLBF's Weaknesses?

Negative profit margin indicating challenges in achieving profitability.

• OTC trading status may limit visibility and liquidity compared to major exchanges.
• Dependence on regulatory environment which can impact operations.

What Could Drive CRLBF Stock Higher?

Expansion into new states as cannabis legalization progresses.

• Development of new product lines to meet consumer demand.
• Strategic partnerships to enhance distribution capabilities.
• Anticipated regulatory changes that could benefit market access.
• Continued investment in marketing and brand awareness initiatives.

What Are the Key Risks for CRLBF?

Financial-distress signal — its Altman Z-Score of -0.75 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-35.3%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Regulatory changes that could impact market access and operations.
• Intense competition from established cannabis operators.
• Market volatility affecting cannabis pricing and consumer demand.
• Challenges related to liquidity due to OTC trading status.

What Are the Growth Opportunities for CRLBF?

• Market Expansion: Cresco Labs has the opportunity to expand its retail footprint beyond its current 48 dispensaries. As more states legalize cannabis, the company can capitalize on new markets, potentially increasing its revenue significantly.
• Product Diversification: With a strong portfolio of brands, Cresco Labs can continue to innovate and introduce new products tailored to consumer preferences. The demand for cannabis-infused edibles and wellness products is on the rise, and Cresco's existing brands like Mindy's Edibles and Remedi position the company well to capture this growing segment.
• Strategic Partnerships: Forming strategic partnerships with other companies in the cannabis space can enhance Cresco Labs' distribution capabilities and brand reach. Collaborations with established brands or retailers can help the company penetrate new markets more effectively and increase its overall sales.
• Regulatory Advancement: As legislation around cannabis continues to evolve, Cresco Labs could benefit from favorable regulatory changes that expand market access. The potential for federal legalization or more lenient state regulations could significantly enhance the company's growth prospects and operational capabilities.
• Increased Consumer Acceptance: Growing public acceptance of cannabis products, particularly for medical use, presents an opportunity for Cresco Labs to increase its customer base. As awareness and education around cannabis benefits improve, the company can leverage its established brand reputation to attract new consumers.

What Are CRLBF's Competitive Advantages?

• Established brand portfolio with recognized names in the cannabis market.
• Multi-state operational presence providing competitive advantages in distribution.
• Strong compliance and regulatory expertise in navigating the cannabis landscape.
• Diverse product offerings catering to a wide range of consumer preferences.
• Significant retail network enhancing consumer access to products.

What Does CRLBF Do?

Cresco Labs Inc., established in 2013 and headquartered in Chicago, Illinois, is a prominent player in the cannabis industry, focusing on the cultivation, production, and distribution of medical and recreational cannabis products across the United States. The company has developed a comprehensive portfolio of brands that cater to diverse consumer needs. Its flagship brand, Cresco, offers a wide range of products including flowers, vape pens, live resins, disposable pens, and extracts. The High Supply label provides an extensive selection of cannabis products including vape cartridges, flower, and pre-rolls. For those seeking vapes and gummies, the Good News brand is available, while Wonder Wellness Co. specializes in wellness-focused vapes and edibles. The Remedi brand offers tinctures, capsules, and salves, focusing on wellness applications, and the Reserve brand provides a general range of cannabis products. Premium cannabis flowers are marketed under the FloraCal brand, while Mindy's Edibles features a variety of cannabis-infused chocolates and gummies. Cresco Labs also holds a license for the Kiva brand, known for its high-quality cannabis-infused edibles. As of January 27, 2022, Cresco Labs operated 48 owned dispensaries, showcasing its extensive retail network. The company's strategic focus on brand diversification and multi-state operations positions it well to capitalize on the growing demand for cannabis products in the U.S.

What Products and Services Does CRLBF Offer?

• Cultivate and produce medical and recreational cannabis products.
• Operate a diverse portfolio of cannabis brands catering to various consumer needs.
• Manage a network of dispensaries for direct retail sales.
• Develop and market cannabis-infused edibles and wellness products.
• Engage in wholesale distribution of cannabis products to other retailers.
• Focus on compliance with state and federal regulations in the cannabis industry.

How Does CRLBF Make Money?

• Generate revenue through the sale of cannabis products in owned dispensaries.
• Wholesale distribution of cannabis products to other retailers and dispensaries.
• Leverage brand portfolio to capture a wide range of consumer preferences.
• Focus on product innovation to meet evolving market demands.
• Utilize economies of scale in cultivation and production to enhance profitability.

What Industry Does CRLBF Operate In?

The cannabis industry is experiencing rapid growth, driven by increasing legalization and consumer acceptance of cannabis products for both medical and recreational use. Cresco Labs operates in a competitive landscape with several key players, including Curaleaf and Trulieve, which are also expanding their market presence. The evolving regulatory environment presents both opportunities and challenges, as companies must navigate varying state laws and compliance requirements.

Who Are CRLBF's Key Customers?

• Medical cannabis patients seeking therapeutic products.
• Recreational consumers looking for various cannabis formulations.
• Retail dispensaries purchasing products for resale.
• Health-conscious consumers interested in wellness-focused cannabis products.
• Edible consumers seeking cannabis-infused snacks and treats.

Cresco Labs Inc. (CRLBF) Valuation Context

Valued at $258M, CRLBF is classified as a micro-cap stock. Relative to its peer group, CRLBF's quantitative score of 45/100 is roughly in line with the peer average of 55/100.

CRLBF Revenue & Earnings Trend

In Q2 FY2026, CRLBF generated $173.3M in top-line revenue, marking a sequential increase of 16.2%. The company recorded net income of $16.8M, with diluted EPS of $0.04. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CRLBF averaged $-0.08 in diluted EPS.

Company Profile

Cresco Labs Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Charles Bachtell. CRLBF has traded publicly since 2018.

Return on equity for Cresco Labs Inc. stands at -35.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -45.2%, the inverse of the P/E and a quick read on earnings relative to price.

Cresco Labs Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.75 places it in the distress zone, a signal of elevated financial risk.

Cresco Labs Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 182.7% below estimates on average.

CRLBF Financials

CRLBF Latest News

CRLBF Analyst Consensus

CRLBF MoonshotScore

Cresco Labs Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources